Table 2.
Estimated odds ratios of the comparators in HEC and MEC.
| HEC APPAa |
MEC PAb |
|
|---|---|---|
| OR (95% CI) | OR (95% CI) | |
| Acute phase | ||
| Complete response | 1.498 (0.217–6.385) | 1.345 (0.879–2.063) |
| Complete protection | 3.501 (1.088–13.263) | 1.084 (0.745–1.577) |
| Overall phase | ||
| Complete response | 2.490 (1.103–6.092) | 1.450 (1.050–2.003) |
| Complete protection | 3.501 (1.088–13.263) | 1.281 (0.947–1.724) |
a
aprepitant+palonosetron+dexamethasone;
b
palonosetron+dexamethasone.
CI: confidence interval; HEC: highly emetogenic chemotherapy; MEC: moderately emetogenic chemotherapy; NEPA: netupitant+palonosetron+ dexamethasone; OR: odds ratio.
Reference efficacy was NEPA from NETU 07–07 and NETU 08–18 for HEC and MEC, respectively.